Rituximab biosimilar is under clinical development by Nichi-Iko Pharmaceutical and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Rituximab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rituximab biosimilar overview

Rituximab biosimilar (AP-056) is under development for the treatment of lymphoma. It is administered as intravenous injection. The drug candidate acts by targeting the B lymphocyte antigen CD20. It was under development for the treatment of B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia (CLL), transplant rejection, Wegener’s Granulomatosis and rheumatoid arthritis (RA).

Nichi-Iko Pharmaceutical overview

Nichi-Iko Pharmaceutical (Nichi-Iko) is a manufacturer of generic pharmaceutical products. The company portfolio includes anti-platelets, anti-allergens, anti-diabetics, prostaglandins, anti-infectives, non-steroidal anti-inflammatory drugs, quasi-drugs and generic drugs for critical care and for the treatment of circulatory system, digestive system, respiratory system, central peripheral nervous system, cardiovascular diseases, and cancer. Nichi-Iko also offers medicines in various forms including oral disintegration tablets, chewable tablets, gels, capsules, and powders. It has operations in Hong Kong, Thailand, Malaysia, Vietnam, the Philippines, and Singapore. Nichi-Iko is headquartered in Toyama, Japan.

For a complete picture of Rituximab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.